SPOTLIGHT: Organogenesis plans expansion

With the help of state funds, Organogenesis is beefing up its operations in Massachusetts. The company, which makes regenerative medicine products, says it was persuaded to stay and grow in Massachusetts because of the state's new program to encourage the biotech field. Release | Report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.